Merck KGaA Drops Parkinson’s Treatment Sarizotan
This article was originally published in The Pink Sheet Daily
Executive Summary
Disappointing Phase III trial results led to the decision.
You may also be interested in...
Merck Serono Extends CNS Collaboration With Newron, Invests In Israel
Merck Serono's revised deal with Newron gives the latter a license to develop two additional compounds, with Merck holding a buy-back option.
Merck Serono Extends CNS Collaboration With Newron, Invests In Israel
Merck Serono's revised deal with Newron gives the latter a license to develop two additional compounds, with Merck holding a buy-back option.
Merck KGaA Buys Serono, Gaining U.S. Commercial Organization
Merck acquires family-owned shares representing 64.5% of Serono's capital and will launch a tender offer for the remainder, at a total value of $13.27 bil.